Hostname: page-component-78c5997874-mlc7c Total loading time: 0 Render date: 2024-11-08T07:31:00.077Z Has data issue: false hasContentIssue false

Molecular-based diagnosis of Entamoeba histolytica infection

Published online by Cambridge University Press:  11 February 2004

Christopher D. Huston
Affiliation:
University of Virginia Health Sciences Center, MR-4 Building, Room 2115, Charlottesville, VA 22908, USA.
Rashidul Haque
Affiliation:
Parasitology Laboratory, International Centre for Diarrhoeal Disease Research, GPO Box 128, Dhaka 1000, Bangladesh.
William A. Petri
Affiliation:
University of Virginia Health Sciences Center, MR-4 Building, Room 2115, Charlottesville, VA 22908, USA.

Abstract

Infection with Entamoeba histolytica, the protozoan parasite that causes amoebic colitis and liver abscess, results in 34 million to 50 million symptomatic cases of amoebiasis (all illnesses caused by E. histolytica, including amoebic dysentery) worldwide each year, causing 40 thousand to 100 thousand deaths annually. As a result of accruing biochemical, genetic and immunological data, E. histolytica was re-defined in 1993 to recognise the existence of two morphologically identical but genetically distinct human parasites: E. histolytica, the aetiological agent of invasive intestinal and extraintestinal amoebiasis, and Entamoeba dispar, a non-pathogenic intestinal parasite. Because microscopy is unable to distinguish between these two organisms, it should no longer be relied upon to diagnose amoebiasis. Sensitive and specific molecular techniques that are able to distinguish E. histolytica from E. dispar have been developed recently; they include (1) the detection of an E. histolytica antigen using an enzyme-linked immunosorbent assay (ELISA), (2) the use of the polymerase chain reaction (PCR) to amplify amoebic DNA, and (3) the culture of stool samples followed by isoenzyme analysis. Of these three test methods, only antigen detection using ELISA can be performed rapidly and easily, making it the diagnostic test method of choice for clinical use in the developing world, where the morbidity and mortality caused by E. histolytica are greatest. However, the PCR method is a powerful tool for the genetic typing of different amoebic strains. Together these two methods should result in both improved clinical diagnosis and treatment of amoebiasis, and a greater understanding of the epidemiology of E. histolytica. Such knowledge will not only assist public health efforts to control amoebiasis, but also facilitate the careful testing of the anti-amoebic vaccines that are currently being developed.

Type
Review Article
Copyright
© Cambridge University Press 1999

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)